Immunomodulatory activities of statins

Japanese Journal of Clinical Immunology

Volumn 27, Issue 6, 2004, Pages 357-360

  Okazaki, Hitoaki ^a   Nagashima, Takao ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

apoptosis; immunodulatory activities; pleiotropic effect; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR;

ANIMAL; HUMAN; REVIEW;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS;

EID: 17144412555     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.27.357     Document Type: Article

References (13)

1. Vaughan C. J., et al.: Statins do more than just lower cholesterol. Lancet 348:1079–1082, 1996.
2. Llevadot J., et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399–405, 2001.
3. Albert M. A., et al.: Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286: 64–70,2001.
4. Mundy G., et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–1949, 1999.
5. Kobashigawa J. A., et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621–627, 1995.
6. Katznelson S., et al.: The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 17: 335–340, 1998.
7. Katznelson S., et al.: Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int 48: S112-S115, 1995.
8. Kwak B., et al.: Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399–1402, 2000.
9. Weitz-Schmidt G., et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687–692, 2001.
10. McCarey D. W., et al.: Trial of atorvastatin in rheumatoid arthritis (TRRA): double-blind, randomized placebo-control trial. Lancet 363: 2015–2021, 2004.
11. Vollmer T., et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607–1608, 2004.
12. Meroni P. L., et al.: Statins prevent endothelial cell activation induced by antiphospholipid (anti-b2-glycoprotein I) antibodies. Effect on the proadhesive ad proinflammatory phenotype. Arthritis Rheum 44: 2870–2878, 2001.
13. Okazaki H., et al.: Effects of FTY720 in MRL-lpr/lpr mice: Therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707–716, 2002.